Title:
OPTIMIZED ANTI-TL1A ANTIBODIES
Document Type and Number:
Japanese Patent JP2023166402
Kind Code:
A
Abstract:
To provide novel therapeutics to treat IBD that specifically target enzymes involved in pathogenesis of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).SOLUTION: The present invention provides humanized anti-TL1A antibodies and pharmaceutical compositions, wherein the antibodies possess superior therapeutic aspects compared to other tumor necrosis factor ligand 1A (TL1A) binding antibodies. The antibodies possess high sequence homology to human germline networks while still exhibiting high binding affinity, express at high levels in bacterial and mammalian culture, and possess fewer sequence liabilities, such as deamidation sites, that lead to increased degradation and reduced therapeutic effect.SELECTED DRAWING: Figure 5
Inventors:
WATKINS JEFFRY D
CINDY T DICKERSON
J MONTY WATKINS
PATRICIA MCNEELEY
CINDY T DICKERSON
J MONTY WATKINS
PATRICIA MCNEELEY
Application Number:
JP2023131429A
Publication Date:
November 21, 2023
Filing Date:
August 10, 2023
Export Citation:
Assignee:
PROMETHEUS BIOSCIENCES INC
International Classes:
C07K16/18; A61K39/395; A61P1/00; A61P1/04; A61P43/00
Attorney, Agent or Firm:
Kiyohara International Patent Office